GOECP/SEOR radiotheraphy guidelines for non-small-cell lung cancer

Table 7 Dose constraints in normofractionated radiotherapy

Organ	Volume	Endpoint	Dose (Gy), dose/volume	Rate, %	Ref.
Spinal cord	Partial	Myelopathy	Dmax 50, Dmax 60, Dmax 69	0.2%, 6%, 50%
Lung	Whole organ, both lungs	Pneumonitis	V20 ≤ 30%, MD = 7, MD = 13, MD = 20, MD = 24, MD = 27	< 20%, 5%, 10%, 20%, 30%, 40%	Palma et al[133], 2013 Marks et al[130], 2010
Esophagus	Whole organ	≥ Grade 3 acute esophagitis, ≥ grade 2 acute esophagitis	MD < 34, V60 ≤ 17%, V35 < 50%, V50 < 40%, V70 < 20%	5%-20%, < 30%, < 30%, < 30%	Al-Halabi et al[135], 2015
Heart	Pericardium. Whole organ	Pericarditis. Cardiac mortality long term	MD < 26, V30 < 46%, V25 < 10%, V50 ≤ 25%	< 15%, < 15%, < 1%	Speirs et al[136], 2017
Brachial plexus	Whole organ	Brachial plexopathy	MD > 69 Gy. Dosis maximum 75 Gy to 2 cc of the brachial plexus		Amini et al[137], 2012

Dmax: Maximum dose; MD: Median dose.